Prevention of Venous Thromboembolism, 2nd Edition: Korean Society of Thrombosis and Hemostasis Evidence-Based Clinical Practice Guidelines

Soo-Mee Bang, Moon Ju Jang, Kyoung Ha Kim, Ho-Young Yhim, Yeo-Kyeoung Kim, Seung-Hyun Nam, Hun Gyu Hwang, Sung Hwa Bae, Sung-Hyun Kim, Yeung-Chul Mun, Yang-Ki Kim, Inho Kim, Won-II Choi, Chul Won Jung, Nan Hee Park, Nam-Kyong Choi, Byung-Joo Park, and Doyeun Oh

1Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam; 2Department of Internal Medicine, School of Medicine, CHA University, Seongnam; 3Department of Internal Medicine, Soonchunhyang University College of Medicine, Seoul; 4Department of Internal Medicine, Chonbuk National University Medical School, Jeonju; 5Department of Internal Medicine, Chonnam National University Medical School, Gwangju; 6Department of Internal Medicine, Catholic University of Daegu School of Medicine, Daegu; 7Department of Internal Medicine, Dong-A University College of Medicine, Busan; 8Department of Internal Medicine, Ewha Womans University School of Medicine, Seoul; 9Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, Seoul; 10Department of Internal Medicine, Dongsan Hospital, Keimyung University School of Medicine, Daegu; 11Department of Internal Medicine, Gumi; 12Department of Internal Medicine, Catholic University of Daegu School of Medicine, Daegu; 13Department of Internal Medicine, VHS Medical Research Collaborating Center, Seoul National University Hospital, Seoul; 14Department of Preventive Medicine, Seoul National University College of Medicine, Seoul, Korea

Received: 28 October 2013
Accepted: 29 November 2013

Keywords: Guideline; Prevention; Venous Thromboembolism; Bleeding

INTRODUCTION

Venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE), is a major cause of morbidity and mortality in hospitalized patients. PE is the third most common fatal vascular disorder following coronary artery disease and cerebrovascular accident (1); it is also the leading cause of preventable hospital death and a major cause of maternal mortality (2, 3). In addition to the clinical impact of VTE on morbidity and mortality, the economic burden of the disease is considerable (4). Thus, VTE is a major public health concern in developed countries.

For the treatment of VTE, thromboprophylaxis has been recommended based on the four following factors: the high incidence of VTE in hospitalized patients; the difficulty of early diagnosis due to vague symptomatology; the cost-effectiveness of medical prophylaxis; and the high mortality of PE without early diagnosis and prompt management. Furthermore, data from numerous clinical trials have demonstrated that appropriate prophylaxis to prevent VTE is safe and effective in both surgical and medical patients. Based on these results, several evidence-based guidelines have been proposed for VTE prevention (5-8). Recently, the American College of Chest Physicians (ACCP) issued the evidence-based clinical practice guideline for antithrombotic therapy and prevention of thrombosis, which provides improved guidelines in an American setting (9th edition) (6).

The incidence of VTE is lower in the Korean population than in the Caucasian population; however, it appears to be rapidly increasing in response to the widespread adop-
tion of the Western lifestyle. Additionally, the large proportion of the Korean population is comprised of the elderly, and advanced age has been recognized as a risk factor for VTE (9). After we proposed the first Korean Guideline for the Prevention of VTE in 2010 (10), awareness of the significance and risk of VTE has been increasing among both the public health community and physicians in Korea. However, the previous guidelines were not based on clinical evidence, but on a consensus of the opinions of the expert panel of the Korean Society of Thrombosis and Hemostasis with references of the second edition of the Japanese guidelines for the prevention of VTE, and the ACCP guidelines (8th edition).

We recently revised the Korean guidelines for VTE prevention based on the Health Insurance Review and Assessment Service (HIRA) database (11) and new ACCP guidelines (6). These guidelines were established to reflect Korean VTE epidemiology and serve as practical recommendations for physicians in Korea. They focus on patients undergoing major surgery and are intended to assist physicians in balancing the risks of death and morbidity from VTE against the complications and disadvantages of prophylaxis. Unfortunately, the extended content of these guidelines can be too much complex for physicians. This article represents a simplified, practical version of the revised guidelines that provide an overview of the key issues that are relevant to physicians. These guidelines stratify patients into 4 risk groups (very low, low, moderate, and high) according to the actual VTE risk and recommend an optimal VTE prophylaxis for each group.

**GENERAL RECOMMENDATIONS**

**Risk stratification**

The VTE risk of all hospitalized patients should be assessed using an accepted risk stratification method. Additionally, the method for risk stratification should be simple, efficient, and cost-effective. Classic risk factors for VTE include cancer, surgery, prolonged immobilization, fractures, puerperium, paralytic ileus, use of oral contraceptives, antiphospholipid antibody syndrome, and other acquired or hereditary thrombophilic conditions. Most hospitalized patients have at least one risk factor for VTE, and decisions regarding the risk of VTE should include considerations of current and future thrombotic risks (12).

The ACCP Evidenced-Based Clinical Practice Guidelines (9th Edition) for the Prevention of VTE suggests a risk stratification model based on the symptomatic VTE rate (13). This model classifies patients into very low risk (<0.5%), low risk (0.5%-1.5%), moderate risk (1.5%-3.0%), and high risk (>3%) groups, depending on the symptomatic VTE rate. Because the ultimate target of VTE prevention is symptomatic VTE, this approach is both simple and practical. Thus, we used this risk-stratification method in the development of our revised guidelines.

**Non-pharmacologic thromboprophylaxis**

Ambulation increases venous blood flow and reduces venous stasis. Early ambulation is a simple measure that should be applied as standard practice to prevent VTE in all patients. Mechanical prophylaxis, including graduated compression stocking (GCS) and intermittent pneumatic compression (IPC), focuses on reducing venous stasis and blood stagnation by promoting venous blood flow through external compression. Mechanical methods have an additional advantage in that they are not associated with a risk of bleeding. Mechanical prophylaxis is recommended as an alternative to or in combination with pharmacological prophylaxis. The benefits of decreasing VTE risk were similar irrespective of the mechanical method used.

**Pharmacologic thromboprophylaxis**

Pharmacological prophylaxis is both reasonable and cost-effective and is therefore recommended as the initial form of prophylaxis in most patients without a high risk of bleeding. Effective pharmacological prophylaxis may include low-molecular-weight heparin (LMWH; 20-100 U/kg (0.2-1 mg/kg) subcutaneously [SC] daily), low-dose unfractionated heparin (LDUH; 5,000 U every 8-12 hr SC), fondaparinux (2.5 mg SC daily), rivaroxaban (10 mg orally daily), dabigatran (150 mg orally each day), apixaban (2.5 mg every 12 hr orally), aspirin (100 mg orally each day), and warfarin (daily doses to maintain an international normalized ratio [INR] of 1.5-2.5) (Table 1). The duration of prophylaxis depends on the perceived benefits of anticoagulation versus the risks of bleeding and overall cost. Currently, dabigatran and apixaban are not approved by the Korean FDA for thromboprophylaxis.

**Stratification of VTE risk in hospitalized patients**

Based on the risk stratification for individual patients, the risk of VTE can be stratified from very low to high (Table 2). However, the prophylactic treatment selected is not solely procedure-specific, but depends on the individual’s level of risk based on care.
ful risk assessment. We defined patients at very low risk as those undergoing surgery for breast cancer, gastric cancer (< 60 yr), or hepatobiliary cancer (< 60 yr); cesarean section, hysterectomy, or oophorectomy for benign disease; and transurethral resection of the prostate, nephrectomy, cystectomy, or prostatectomy for benign or malignant disease. For patients undergoing gastric cancer surgery (≥ 60 yr), hepatobiliary cancer surgery (≥ 60 yr), or hysterectomy (cervical cancer), we define these patients as low risk. Moderate-risk patients are defined as those undergoing surgery for colorectal, pancreatic, ovarian, or esophageal cancer; total hip arthroplasty (THA); total knee arthroplasty (TKA); or hip fracture surgery (HFS). If the moderate risk patients have an additional risk factor, including previous VTE or thrombophilia, we define these patients as high-risk patients.

**Thromboprophylaxis according to risk stratification**

We recommend the selection of an optimal prophylactic treatment based on VTE risk levels. Generally, mechanical prophylaxis is recommended for low or moderate risk patients, and pharmacological prophylaxis is recommended for moderate or high-risk patients. For patients with very low risk of VTE, we recommend early ambulation or exercise only; for patients with low risk of VTE, we recommend mechanical prophylaxis with GCS or IPC; for patients with moderate risk of VTE, we recommend mechanical or pharmacological prophylaxis; and for patients with high risk of VTE, we recommend pharmacological prophylaxis with or without a mechanical method.

**Grade of recommendation**

We adopted the quality of evidence and strength of recommendations from the 9th ACCP guidelines (13). The grade of recommendation indicates the strength of the guideline and the degree of consensus agreement. We define the Grade IA as a strong recommendation with high-quality evidence; Grade 1B as a strong recommendation with moderate-quality evidence; Grade 1C as a strong recommendation with low- or very-low-quality evidence; Grade 2A as a weak recommendation with high-quality evidence; Grade 2B as a weak recommendation with mod-

---

**Table 2. VTE risk stratification and recommended prophylactic methods for each risk group**

| Risk groups | Surgery or condition | Prophylaxis |
|-------------|---------------------|-------------|
| Very low    | Breast cancer       | Early ambulation |
|             | Gastric cancer (< 60 yr) |             |
|             | Hepatobiliary cancer (< 60 yr) |             |
|             | Cesarean section    |             |
|             | Hysterectomy of benign disease |             |
|             | Oophorectomy of benign disease |             |
|             | Nephrectomy         |             |
|             | Cystectomy          |             |
|             | Prostatectomy       |             |
|             | Transurethral resection of the prostate |             |
| Low         | Gastric cancer (≥ 60 yr) | Mechanical prophylaxis |
|             | Hepatobiliary cancer (≥ 60 yr) |             |
|             | Cervical cancer     |             |
| Moderate    | Colorectal cancer   | Mechanical prophylaxis* or pharmacological prophylaxis |
|             | Pancreatic cancer   |             |
|             | Ovarian cancer      |             |
|             | Esophageal cancer   |             |
|             | Major orthopedic surgery (THA, TKA, or HFS) |             |
|             | Major trauma        |             |
| High        | Any cancer surgery in patients with previous VTE or thrombophilia | Pharmacological prophylaxis (± mechanical prophylaxis) |
|             | Major orthopedic surgery with risk (advanced age, previous VTE or thrombophilia) |             |
|             | Spinal cord injury  |             |

VTE, venous thromboembolism; VTE, *Recommended in patients with risk of bleeding; THA, total hip arthroplasty; TKA, total knee arthroplasty; HFS, hip fracture surgery.

---

**Table 3. Strength of recommendations and quality of evidence**

| Level of recommendation | Definition |
|-------------------------|------------|
| 1                       | Strong recommendation: Medical and economic benefits are definite |
| 2                       | Weak recommendation: Medical and economic benefits are suggestive of some benefit; the evidence is not sufficient to make a strong recommendation |

| Quality of evidence | Definition |
|---------------------|------------|
| A                   | High-quality evidence: Evidence from a meta-analysis of randomized controlled trials or at least one or more randomized controlled trial(s) |
| B                   | Moderate-quality evidence: Evidence from a randomized controlled study with a serious limitation or large-scale observational studies |
| C                   | Low- or very low-quality evidence: Evidence from small-scale observational studies or non-experimental descriptive studies such as comparative studies, correlation studies, case-control studies, or expert opinions |
erate-quality evidence; and Grade 2C as a weak recommendation with low- or very-low-quality evidence (Table 3).

**GENERAL SURGERY**

The principles of risk stratification for general surgery are based on the type of surgery (cancer or non-cancer), the type of cancer (gastric, colorectal, hepatobiliary, or breast), age (< 60 yr, and ≥ 60 yr), and the presence of previous VTE. According to these principles, patients were classified into four risk groups.

We define the very-low-risk group as patients scheduled for non-cancer surgery or breast cancer surgery and patients (< 60 yr) scheduled for gastric or hepatobiliary cancer surgery. For very-low-risk patients, we recommend early and frequent ambulation (Grade 2C). For patients (≥ 60 yr) undergoing gastric or hepatobiliary cancer surgery, we recommend mechanical prophylaxis with GCS or IPC (Grade 2C). We recommend mechanical prophylaxis with GCS or IPC for patients undergoing colorectal or pancreatic cancer surgery, but pharmacological prophylaxis with LMWH or LDUH may also be used for patients with a low risk of bleeding (Grade 2C). If patients undergoing any cancer surgery have an additional risk factor, including previous VTE or thrombophilia, we recommend pharmacological prophylaxis with LMWH or LDUH (Grade 1B) (Table 4).

**ORTHOPEDIC SURGERY**

Patients undergoing major orthopedic surgery, which includes total hip arthroplasty (THA), total knee arthroplasty (TKA), and hip fracture surgery (HFS), are at particularly high risk for VTE. Although routine prophylaxis is adopted these high-risk patients, the rate of clinically overt VTE in these patients remains at approximately 1.8% (14). Recently, a prospective study reported that the rate of symptomatic VTE is 1.5% in Asian patients who have a major orthopedic surgery without VTE prophylaxis (15). The HIRA database also revealed that the rate of symptomatic VTE is 1.08% for TKA, 0.98% for THA, and 1.60% for HFS. Based on these results, we classified the patients scheduled for major orthopedic surgery into the moderate-risk group for VTE.

We recommend pharmacological or mechanical prophylaxis for patients scheduled for major orthopedic surgery for at least 10-14 days (Grade 2A). We recommend pharmacological prophylaxis (LMWH, fondaparinux, dabigatran, apixaban, rivaroxaban, LDUH, warfarin, or aspirin) for patients undergoing TKA and THA, and mechanical prophylaxis for patients with a risk of bleeding. For patients undergoing HFS, we recommend pharmacological (LMWH, fondaparinux, LDUH, warfarin, or aspirin) or mechanical prophylaxis. For all patients undergoing major orthopedic surgery, we recommend mechanical prophylaxis (Grade 2B). If the patients have an additional risk factor, including advanced age, general anesthesia, previous VTE, or cancer, we recommend pharmacological prophylaxis (Grade 2B). Early ambulation should be encouraged for all patients after surgery (Grade 1A). Routine screening is not recommended in these patients (Grade 1A) (Table 5).

---

| Risk groups | Procedures                      | Prophylaxis                      | Grade of recommendation |
|-------------|---------------------------------|----------------------------------|-------------------------|
| Very low    | Breast cancer surgery (< 60 yr of age) | Early ambulation                  | 2C                      |
|             | Gastric cancer surgery (< 60 yr of age) |  |                          |
|             | Hepatobiliary cancer surgery (< 60 yr of age) |  |                          |
| Low         | Gastric cancer surgery (≥ 60 yr of age) | Mechanical prophylaxis             | 2C                      |
|             | Hepatobiliary cancer surgery (≥ 60 yr of age) |  |                          |
| Moderate    | Colorectal cancer surgery       | Mechanical prophylaxis or pharmacological prophylaxis | 2C                      |
|             | Pancreatic cancer surgery       |  |                          |
| High        | Any major cancer surgery in patients with previous VTE or thrombophilia | Pharmacological prophylaxis (± mechanical prophylaxis) | 1B                      |

VTE, venous thromboembolism.

---

| Risk groups | Procedures                      | Prophylaxis                      | Grade of recommendation |
|-------------|---------------------------------|----------------------------------|-------------------------|
| Moderate    | THA, TKA                        | Mechanical prophylaxis (GCS, IPC)* or Pharmacological prophylaxis (LMWH, LDUH, fondaparinux, rivaroxaban, dabigatran, apixaban, warfarin, or aspirin) | 2A                      |
|             | HFS                             | Mechanical prophylaxis (GCS, IPC)* or Pharmacological prophylaxis (LMWH, LDUH, fondaparinux, warfarin, or aspirin) | 2A                      |
| High        | THA or TKA with risk (advanced age, previous VTE or thrombophilia) | Pharmacological prophylaxis (LMWH, LDUH, fondaparinux, rivaroxaban, dabigatran, apixaban, or warfarin) | 2A                      |
|             | HFS with risk (advanced age, previous VTE or thrombophilia) | Pharmacological prophylaxis (LMWH, LDUH, fondaparinux, or warfarin) | 2A                      |

VTE, venous thromboembolism; *Recommended in patients with a risk of bleeding; consider switching to anticoagulants when the bleeding risk abates. THA, total hip arthroplasty; TKA, total knee arthroplasty; HFS, hip fracture surgery; GCS, graduated compression stockings; IPC, intermittent pneumatic compression; LMWH, low-molecular-weight heparin; LDUH, low-dose unfractionated heparin.

---

http://dx.doi.org/10.3346/jkms.2014.29.2.164
NEUROSURGERY

Neurosurgical patients are at an increased risk of both thrombosis and bleeding. The incidence of DVT and subsequent PE in neurosurgery patients has been reported to be as high as 25%, and the PE mortality rate has been reported to range from 9% to 50% (16, 17). The important risk factors in neurosurgical surgery are the type of surgery (cranial, spinal, or vascular), duration of surgery, cancer, infection, immobilization, venous stasis, chronic lower extremity swelling, lower extremity trauma, advanced age, CHF; obesity, and sleep apnea. The HIRA database revealed that the rate of DVT is 0.14% and the rate of PE is 0.24% in patients who have undergone brain tumor surgery. We recommend mechanical prophylaxis for all neurosurgery patients (Grade 2C). If the patients have an additional risk factor, including advanced age, female, previous VTE, or brain cancer, we selectively recommend pharmacological prophylaxis (Grade 2C). Patients should be closely monitored for signs of bleeding during pharmacological prophylaxis (Grade 1A).

UROLOGIC SURGERY

The important risk factors for the development of VTE in urological surgery patients are advanced age, obesity, cancer, and previous VTE. The HIRA database shows that the rate of VTE is 0.35% in kidney cancer patients who underwent nephrectomy, 0.17% in bladder cancer patients with cystectomy, 0.22% in prostate cancer patient with prostatectomy, and 0.06% in prostate hyperplasia patients who received transurethral resection of the prostate. Based on these results, we classified patients with these urologic surgeries into the very-low-risk group.

We recommend early and frequent ambulation for transurethral resection of the prostate (Grade 2A). For cancer patients undergoing nephrectomy, cystectomy, and prostatectomy, early and frequent ambulation is recommended (Grade 2B). For patients with previous VTE or thrombophilia and elderly patients (≥ 60 yr) scheduled for major urologic surgery under general anesthesia, we recommend mechanical prophylaxis or pharmacological prophylaxis (LMWH or LDUH) or a combination of both pharmacological and mechanical prophylaxis (Grade 2B).

OBSTETRIC AND GYNECOLOGIC SURGERY

The incidence of VTE is higher during pregnancy and may occur at any stage of pregnancy or in the weeks following delivery. The risk factors for VTE in pregnant women include previous VTE, a family history of VTE, presence of anti-phospholipid antibody, age ≥ 40 yr, prolonged bed rest, placenta previa, Cesarean section, and lower-extremity varicosities. The HIRA database shows that the incidence of pregnancy-associated VTE is 0.82 per 10,000 deliveries (18).

We suggest that a thrombosis risk assessment be carried out in all women during pregnancy (Grade 1A). Early ambulation should be encouraged for all postpartum women (Grade 1A). For postpartum women without any risk factor for VTE, we do not recommend mechanical or pharmacological prophylaxis regardless of delivery mode (Grade 2A). Further, we do not recommend routine thrombophilia testing (Grade 1B). For pregnant women with hereditary thrombophilia, positive anti-phospholipid antibody, or previous VTE, antepartum plus postpartum prophylaxis is recommended (Grade 1B). Warfarin is contraindicated during pregnancy (category X) (Grade 1A) (19). However, warfarin can replace LMWH after delivery for postpartum thromboprophylaxis (20) (Grade 1B).

The risk factors for VTE associated with gynecologic surgery are giant uterine myoma, previous surgery for an ovarian tumor, ovarian cancer, uterine or cervical cancer, severe intrapelvic adhesions, ovarian hyperstimulation syndrome, hormonal therapy, and particularly prolonged lymph node dissection requiring transfusion (21). The HIRA database revealed that rates of VTE are 0.02% for hysterectomy associated with benign disease, 0.59% for hysterectomy associated with cervical cancer, 0.05% for oophorectomy associated with benign disease, and 1.21% for ovariecomy associated with ovarian cancer. We recommend early and frequent ambulation for very-low-risk patients (hysterectomy or oophorectomy with benign disease) (Grade 2B). For low-risk patients undergoing hysterectomy with cervical cancer, mechanical prophylaxis is recommended (Grade 2B). For moderate-risk patients undergoing oophorectomy with ovarian cancer, we recommend pharmacological prophylaxis with LMWH or LDUH (Grade 2B). If moderate-risk patients are at risk of bleeding during anticoagulation therapy, we recommend mechanical prophylaxis (Grade 2B).

MAJOR TRAUMA AND SPINAL CORD INJURY

VTE can cause significant morbidity in patients experiencing major trauma and occurs in up to 50% of patients without prophylaxis (22). Previous studies have identified several risk factors for VTE including age, male gender, pelvic fractures, lower extremity fractures, traumatic brain injury, increased Injury Severity Score, chest injury, operative interventions, and acute spinal cord injury (SCI) (23, 24). We recommend mechanical or pharmacological prophylaxis for major trauma patients (Grade 2C). If the patients have a high risk of bleeding (intracranial bleeding, lung injury, liver injury, spleen injury, and retroperitoneal bleeding associated with pelvic bone fracture), mechanical prophylaxis (GCS or IPC) should be implemented (Grade 2C). When the risk of bleeding has been eliminated, we recommend that pharmacologic prophylaxis with LDUH or LMWH be substituted for the mechanical prophylaxis (Grade 2C). Usually, pharmacological prophylaxis can be used within 36 hr of trauma.
(Grade 2C). We recommend that pharmacological prophylaxis be continued for 3 months following trauma (Grade 2C).

Patients with SCI have been shown to be at higher risk for DVT than many other trauma patients. Overall, the incidence of DVT without prophylaxis is estimated to be 40% based on a meta-analysis of DVT in patients with acute spinal cord injury (25). Moreover, prevention of VTE is important because PE is a leading cause of death in SCI patients (26). We recommend pharmacological prophylaxis with LDUH, LMWH, or warfarin for SCI patients without a risk of bleeding (Grade 2C). If the patient is contraindicated for pharmacological prophylaxis, mechanical prophylaxis (GCS or IPC) should be implemented (Grade 2C). We recommend that prophylaxis be continued for 3 months (Grade 2C); however, the duration can be decreased after ambulation (Grade 2C). If patients are complicated with spinal or epidural hematoma, mechanical prophylaxis (GCS or IPC) should be implemented for several days (Grade 2C). When the risk of bleeding has decreased, we recommend that pharmacologic prophylaxis (LDUH or warfarin) be substituted for the mechanical prophylaxis or be combined with mechanical prophylaxis (Grade 2C).

NEURAXIAL ANESTHESIA

Neuraxial anesthesia is a comprehensive term used for spinal, epidural, and caudal blocks. The risk for the development of spinal or epidural hematoma may be elevated by the concomitant use of anticoagulants and antiplatelet agents (27, 28). The established risk factors for spinal or epidural hematoma after neuraxial blockade include an underlying hemostatic disorder, an anatomically deformed vertebral column, traumatic insertion of a needle or catheter, repeated insertion attempts, concomitant anticoagulation, continuous use of epidural catheters, and old age (29, 30).

We recommend against concomitant administration of medications affecting hemostasis, such as antiplatelet drugs or warfarin, during anticoagulation with LMWH or UFH (Grade 1B). The presence of blood during needle and catheter placement does not necessitate postponement of surgery. We suggest that initiation of LMWH therapy in this setting should be delayed for 24 hr postoperatively and that this consideration be discussed with the surgeon (Grade 2C). For patients receiving prophylactic doses of LMWH, we recommend a delay of at least 10-12 hr after the time of needle insertion (Grade 1C). For patients receiving therapeutic doses of LMWH, we recommend a delay of at least 24 hr before the time of needle insertion (Grade 1C). For patients receiving twice-daily dosing of LMWH, the first dose of LMWH should be administered no earlier than 24 hr postoperatively (Grade 1C). If the epidural catheter is left indwelling overnight, administration of LMWH should be delayed for 2 hr after catheter removal (Grade 1C). We recommend that the anticoagulant therapy be discontinued (ideally 4-5 days before the planned procedure) and the INR must be normalized before initiation of neuraxial block (Grade 1B). As prophylaxis with warfarin is initiated, we suggest that neuraxial catheters should be removed when the INR is less than 1.5 (Grade 2C). Cyclooxygenase-2 inhibitors have a minimal effect on platelet function and should be considered in patients who require anti-inflammatory therapy in the presence of anticoagulation (Grade 2C). We recommend an interval between the last dose of clopidogrel or aspirin and neuraxial blockade of at least 7 days (Grade 1C).

MEDICAL CONDITIONS

Hospitalized patients with acute medical conditions are at a significant risk of VTE. Previous studies have shown that in the absence of prophylaxis, a significant proportion of acutely ill medical patients develop VTE, with DVT and PE incidence of 10-30% in general medical patients (31-33). Despite extensive studies in medical patients, the morbidity and mortality of VTE remains significant. The risk of VTE was determined by assessing the probability of VTE in acutely ill medical patients according to predisposing risk factors (age > 70 yr, obesity, long-term immobility, tobacco use, varicosities, dehydration, estrogens, cancer, previous DVT, paraplegia, congenital or acquired thrombophilia, and inflammatory bowel disease) and acute medical illnesses currently under treatment (chronic obstructive pulmonary disease exacerbation, mechanical ventilator therapy, infection, congestive heart failure, and cerebrovascular attack) (34-36).

We recommend routine assessment for VTE risk and bleeding risk in all acutely medically ill patients (Grade 1A). The physician should decide the optimal VTE prophylaxis according to the number of VTE risk factors, level of VTE risk, and risk of bleeding (Grade 2C). For acutely ill medical patients who have one or more additional risk factors, including congestive heart failure, we suggest the use of pharmacological prophylaxis (Grade 1B). The presence of blood during needle and catheter placement does not necessitate postponement of surgery. We suggest that initiation of LMWH therapy in this setting should be delayed for 24 hr postoperatively and that this consideration be discussed with the surgeon (Grade 2C). For patients receiving prophylactic doses of LMWH, we recommend a delay of at least 10-12 hr after the time of needle insertion (Grade 1C). For patients receiving therapeutic doses of LMWH, we recommend a delay of at least 24 hr before the time of needle insertion (Grade 1C). For patients receiving twice-daily dosing of LMWH, the first dose of LMWH should be administered no earlier than 24 hr postoperatively (Grade 1C). If the epidural catheter is left indwelling overnight, administration of LMWH should be delayed for 2 hr after catheter removal (Grade 1C). We recommend that the anticoagulant therapy be discontinued (ideally 4-5 days before the planned procedure) and the INR must be normalized before initiation of neuraxial block (Grade 1B). As prophylaxis with warfarin is initiated, we suggest that neuraxial catheters should be removed when the INR is less than 1.5 (Grade 2C). Cyclooxygenase-2 inhibitors have a minimal effect on platelet function and should be considered in patients who require anti-inflammatory therapy in the presence of anticoagulation (Grade 2C). We recommend an interval between the last dose of clopidogrel or aspirin and neuraxial blockade of at least 7 days (Grade 1C).

Table 6. Levels of VTE risk in medical patients

| Risk groups | Medical illness |
|-------------|----------------|
| **Very low** | Acute exacerbation of COPD without mechanical ventilation |
| **Low**     | Long term immobilization Non-metastatic active cancer Central venous catheterization Nephrotic syndrome Inflammatory bowel disease Thalidomide treatment |
| **Moderate**| Acute exacerbation of COPD with mechanical ventilation Sepsis, MI, CHF (NYHA grade III or IV) Metastatic cancer with immobilization Admitted to intensive care unit |
| **High**    | Severe medical illness with previous VTE or thrombophilia Cerebral stroke complicated with paralysis |

VTE, venous thromboembolism; COPD, chronic obstructive pulmonary disease; MI, myocardial infarction; CHF, congestive Heart failure; NYHA, New York Heart Association.
failure, myocardial infarction, cerebrovascular attack, metastatic cancer, or previous VTE, we recommend pharmacological prophylaxis or mechanical prophylaxis (Grade 2C). The majority of patients admitted to the intensive care unit have multiple risk factors for VTE. These patients should be routinely assessed and offered pharmacological prophylaxis or mechanical prophylaxis (Grade 2A). For metastatic cancer patients who have previous VTE or thrombophilia, we recommend pharmacological prophylaxis (Grade 2A). Mechanical prophylaxis can be used when there is a contraindication to anticoagulation (Grade 1A) (Table 6).

**SUMMARY**

These guidelines emphasize strategies for the prevention of VTE in Korean patients experiencing surgery, pregnancy, trauma, cancer, and acute medical illness. Based on VTE risk factors (age, immobility, history of VTE, co-morbid illness, and type of surgery or trauma), patients can be stratified into very low-, moderate-, and high-risk groups. For high-risk patients (any cancer surgery with previous VTE or thrombophilia, major orthopedic surgery with additional risk, and SCI), pharmacological prophylaxis is recommended. Mechanical prophylaxis should be used primarily in patients with a high risk of bleeding. For moderate-risk patients (colorectal or pancreatic cancer surgery, major orthopedic surgery without additional risk, and major trauma), prophylaxis with a mechanical method (GCS and/or IPC) or a pharmacological method can be used. For low-risk patients (gastric cancer surgery [≥ 60 yr], hepatobiliary cancer surgery [≥ 60 yr], and hysterectomy [cervical cancer]), mechanical prophylaxis is recommended. For very low-risk patients, early and frequent ambulation is the only recommended prophylactic treatment. In conclusion, this article outlines the revised Korean guidelines issued for primary VTE prevention and provides a useful reference for clinicians. These guidelines must be updated based on results of well-controlled studies conducted in Korea. Our guidelines aim to define and clarify an optimal strategy for VTE prevention for patients with VTE risk; however, the ultimate decision should be individualized and determined by the physician.

**DISCLOSURE**

The authors declare that they have no conflicts of interest for this study.

**ORCID**

Soo-Mee Bang  http://orcid.org/0000-0002-0938-3007
Moon Ju Jang  http://orcid.org/0000-0001-7440-7573
Kyoung Ha Kim  http://orcid.org/0000-0001-8842-4761
Ho-Young Yhim  http://orcid.org/0000-0002-1252-5336
Yeo-Kyeoung Kim  http://orcid.org/0000-0001-5447-4285
Seung-Hyun Nam  http://orcid.org/0000-0002-5736-2506
Hun Gyu Hwang  http://orcid.org/0000-0001-9304-7219
Sung Hwa Bae  http://orcid.org/0000-0002-5279-6341
Sung-Hyun Kim  http://orcid.org/0000-0002-5051-2413
Yeung-Chul Mun  http://orcid.org/0000-0002-1882-3983
Yang-Ki Kim  http://orcid.org/0000-0003-4221-6689
Inho Kim  http://orcid.org/0000-0002-3153-6312
Won-Ill Choi  http://orcid.org/0000-0001-7705-0098
Chul Won Jung  http://orcid.org/0000-0002-5474-6807
Nam-Kyong Choi  http://orcid.org/0000-0003-1153-9928
Doyeun Oh  http://orcid.org/0000-0002-6981-3144

**REFERENCES**

1. Anderson FA Jr, Wheeler HB, Goldberg RJ, Hosmer DW, Patwardhan NA, Jovanovic B, Forcier A, Dalen JE. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism: the Worcester DVT Study. Arch Intern Med 1991; 151: 933-8.
2. Beckman MG, Hooper WC, Critchley SE, Ortel TL. Venous thromboembolism: a public health concern. Am J Prev Med 2010; 38: S495-501.
3. Chang J, Elam-Evans LD, Berg CJ, Herron J, Flowers L, Seed KA, Syversen CJ. Pregnancy-related mortality surveillance: United States, 1991-1999. MMWR Surveill Summ 2003; 52: 1-8.
4. Ruppert A, Steinele T, Lees M. Economic burden of venous thromboembolism: a systematic review. J Med Econ 2011; 14: 65-74.
5. Cardiovascular Disease Educational and Research Trust; Cyprus Cardiovascular Disease Educational and Research Trust; European Venous Forum; International Surgical Thrombosis Forum; International Union of Angiology; Union Internationale de Phlébologie. Prevention and treatment of venous thromboembolism: International Consensus Statement (guidelines according to scientific evidence). Int Angiol 2006; 25: 101-61.
6. Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schuënemann HJ; American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis Panel. Executive summary: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: 75-47S.
7. Liew NC, Chang YH, Choi G, Chu PH, Gao X, Gibbs H, Ho CO, Ibrahim H, Kim TK, Kritpracha B, et al. Asian venous thromboembolism guidelines: prevention of venous thromboembolism. Int Angiol 2012; 31: 501-16.
8. Wickham N, Gallus AS, Walters BN, Wilson A; NHMRC VTE Prevention Guideline Adaptation Committee. Prevention of venous thromboembolism in patients admitted to Australian hospitals: summary of National Health and Medical Research Council clinical practice guideline. Intern Med J 2012; 42: 698-708.
9. Jang MJ, Bang SM, Oh D. Incidence of venous thromboembolism in Korea: from the Health Insurance Review and Assessment Service database. J Thromb Haemost 2011; 9: 85-91.
10. Bang SM, Jang MJ, Oh DY, Kim YK, Kim IH, Yoon SS, Yoon HJ, Kim CS, Park SY. Korean guidelines for the prevention of venous thromboembolism. J Korean Med Sci 2010; 25: 1553-9.

11. Bang SM, Jung MJ, Kim KH, Yim HY, Kim YK, Bae SH, Kim SH, Mun YC, Kim IH, Jung CW, et al. Incidence of venous thromboembolism (VTE) after major surgeries and proposal of evidence-based Korean guidelines for the prevention of VTE. In: Reitsma P, Rosendaal F, Levi M, editors. XXIV Congress of the International Society on Thrombosis and Haemostasis and 59th annual SSC meeting, Amsterdam: Wiley-Blackwell, 2013, p339. Available at http://www.eventure-online.com/eventure/publicAbstractView.do?id=215660&ec=6839 [accessed on 6 January 2013].

12. Anderson FA Jr, Wheeler HB, Goldberg RJ, Hosmer DW, Forcier A. The prevalence of risk factors for venous thromboembolism among hospital patients. Arch Intern Med 1992; 152: 1660-4.

13. Guyatt GH, Norris SL, Schulman S, Hirsh J, Eckman MH, Akl EA, Crowther M, Vandvik PO, Eikelboom JW, McDonagh MS, et al. Methodology for the development of antithrombotic therapy and prevention of thrombosis guidelines: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: 535S-705S.

14. Falck-Ytter Y, Francis CW, Johanson NA, Carley C, Dahl OE, Schulman S, Ortel TL, Pauer SG, Colwell CW Jr; American College of Chest Physicians. Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: e278S-325S.

15. Leizorovicz A, Turpie AG, Cohen AT, Wong L, Yoo MC, Yim HY, Kim YK, Mun YC, et al. Prevention of venous thromboembolism after trauma: an analysis of 1602 episodes from the American College of Surgeons National Trauma Data Bank. Ann Surg 2004; 240: 490-6.

16. Shackford SR, Davis JW, Hollingsworth-Friddlund P, Brewer NS, Hoyt DB, Mackersie RC. Venous thromboembolism in patients with major trauma. Am J Surg 1990; 159: 365-9.

17. Merli GJ, Crabbe S, Paluzzi BG, Fritz D. Etiology, incidence, and prevention of deep vein thrombosis in acute spinal cord injury. Arch Phys Med Rehabil 1993; 74: 1199-205.

18. DeVivo MJ, Krause JS, Lammertse DP. Recent trends in mortality and causes of death among persons with spinal cord injury. Arch Phys Med Rehabil 1998; 80: 1411-9.

19. Horlocker TT, Wedel DJ, Benzon H, Brown DL, Enneking FK, Heit JA, Mulroy MF, Rosenquist RW, Rowlingson J, Tryba M, et al. Regional anesthesia in the anticoagulated patient: defining the risks (the second ASRA Consensus Conference on Neuraxial Anesthesia and Anticoagulation). Reg Anesth Pain Med 2003; 28: 172-97.

20. Moen V, Dahlgren N, Irestedt L. Severe neurological complications after central neuraxial blockades in Sweden 1990-1999. Anesthesiology 2004; 101: 950-9.

21. Vandermeulen EP, Van Aken H, Vermyny J. Anticoagulants and spinal-epidural anesthesia. Anesth Analg 1994; 79: 1165-77.

22. Geerts WH, Pineo GE, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 338S-406S.

23. Caprini JA, Arcelus JI, Reyna JJ. Effective risk stratification of surgical and nonsurgical patients for venous thromboembolic disease. Semin Hematol 2001; 38: 12-9.

24. Nicolaides AN, Breddin HK, Fareed J, Goldhaber S, Haas S, Hull R, Kaldiki E, Myers K, Samama M, Sasahara A. Prevention of venous thromboembolism: International Consensus Statement: guidelines compiled in accordance with the scientific evidence. Int Angiol 2001; 20: 1-37.

25. Samama MM, Cohen AT, Darmon JY, Desjardins L, Eldor A, Janbon C, Leizorovicz A, Nguyen H, Olsson CG, Turpie AG, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients: prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med 1999; 341: 783-900.

26. Arcelus JI, Candocia S, Traverso CI, Fabrega E, Caprini JA, Hasty JH. Venous thromboembolism prophylaxis and risk assessment in medical patients. Semin Thromb Hemost 1991; 17: 313-8.

27. Barbar S, Noventa F, Rossetto V, Ferrari A, Brandolini B, Perlati M, De Bon E, Tormene D, Pagnan A, Prandoni P. A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score. J Thromb Haemost 2010; 8: 2450-7.

28. Spyropoulos AC, Anderson FA Jr, Fitzgerald G, Decousus H, Pini M, Chong BH, Zott RB, Bergmann JF, Tapson V, Froehlich JB, et al. Predictive and associative models to identify hospitalized medical patients at risk for VTE. Chest 2011; 140: 706-14.